The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

the right inhaler for the right person. There are various problems in administering asthma and COPD treatment to patients. In asthma, for example, people don't necessarily perceive that they have ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...

Inhalers are handheld devices that deliver ... making them important treatments for asthma and COPD. With Medicare, coverage for prescription drugs you take at home is available through Part ...

“This could influence treatment decisions and improve respiratory health in this high-risk population.” “GLP-1 medications might help lower COPD exacerbation risk by reducing systemic ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...